You are here: Industry Insights > Cancer

News List

Roche partners with Vividion on novel E3 Ligases pharmatimes
May 21, 2020
Roche has signed up for access to Vividion Therapeutics' proteomics screening platform and proprietary small molecule library to target E3 ligases and a range of oncology and immunology therapeutic targets.
COVID-19 related delays to cancer treatment could cost thousands of lives, research shows pharmatimes
May 21, 2020
Scientists at the Institute of Cancer Research (ICR) are warning that delays to cancer surgery and other treatment caused by the COVID-19 pandemic could be linked to thousands of additional deaths in England.
BeyondSpring Granted Patent for Plinabulin americanpharmaceuticalreview
May 18, 2020
BeyondSpring announced the United States Patent and Trademark Office (USPTO) has granted the Company a new patent.
Boehringer Ingelheim acquires Northern Biologics’ preclinical cancer antibody pipeline expresspharma
May 18, 2020
The acquisition provides assets targeting tumour stroma and myeloid cells.
Attenuated Diptheria Toxin Developed by Researchers as Novel Form of Drug Delivery Europeanpharmaceuticalreview
May 07, 2020
A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.
DelMar Updates Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors americanpharmaceuticalreview
May 07, 2020
DelMar Pharmaceuticals has enrolled 22 patients in the adjuvant arm of the Company's ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide -- or TMZ -- maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) ...
AGC Biologics Inks Manufacturing Deal with Faron contractpharma
May 07, 2020
The CDMO will manufacture novel precision cancer immunotherapy treatment Clevegen.
Crescendo links with CRUK to progress cancer therapy pharmatimes
May 06, 2020
Crescendo Biologics and Cancer Research UK have entered into a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.
Bayer faces second investor reckoning over glyphosate litigation expresspharma
April 29, 2020
Criticism from investors at this year’s annual shareholders’ meeting – held in a virtual format with gatherings banned due to the coronavirus – will likely be less scathing than it was in 2019.
NICE backs NHS use of Bayer's Vitrakvi via the CDF pharmatimes
April 26, 2020
Bayer's Vitrakvi (larotrectinib) will be available via the NHS in England and Wales to treat a variety of cancers.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page